Marinus Pharmaceuticals

company

About

Marinus Pharmaceuticals reformulates, develops, and commercializes drugs to treat neurological, psychiatric, and pain disorders.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$60M
Industries
Biopharma,Biotechnology,Health Diagnostics,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2003
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:MRNS
Legal Name
Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.

The company was founded in 2003 and is based in Branford, Connecticut.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
13
$451.86M
Marinus Pharmaceuticals has raised a total of $451.86M in funding over 2 rounds. Their latest funding was raised on Nov 7, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 7, 2022 Post-IPO Equity $60M Detail
Oct 31, 2022 Post-IPO Debt $32.50M 1 Sagard Healthcare Royalty Partners Detail
Apr 4, 2022 Post-IPO Equity $1.23M Detail
Mar 31, 2022 Post-IPO Debt $30M 1 Oaktree Capital Management Detail
May 17, 2021 Post-IPO Debt $45M 1 Oaktree Capital Management Detail

Employee Profiles

Number of Employee Profiles
14
Marinus Pharmaceuticals has 14 current employee profiles, including Board member Harry T. Rein
Board member
Board member
Board member
Executive
Board member